Introduction {#Sec1}
============

Knee osteoarthritis (OA) is a chronic, progressive disease that continues to be one of the leading causes of disability among active patients in the USA. Knee OA results in a decrease in quality of life for those suffering from the disease, as well as a large financial burden on health care systems and society \[[@CR1], [@CR2]\]. The prevalence of symptomatic knee OA in the USA was estimated to be 9.9 million in 2010, and it is estimated that among older adults in the USA, there are over 10 million quality of life years lost annually because of knee OA \[[@CR3], [@CR4]\].

A number of treatment methods are available for managing the symptoms of knee OA. Non-surgical treatments may incorporate changes in diet and exercise, ambulatory aids, simple analgesics, and non-steroidal anti-inflammatory drugs (NSAIDs), while more invasive treatments may include intra-articular injections and surgical interventions like total knee arthroplasty (TKA). Many patients diagnosed with OA may have comorbidities precluding them from some of the available treatment options \[[@CR5]\]. There are also patients that may not demonstrate an adequate response to non-surgical treatments and are unwilling or medically unsuitable to undergo surgical interventions \[[@CR6]\]. Experts argue that it is essential to prolong the period of time between the decline of conservative treatment efficacy and surgical intervention, as having TKA at a younger age may increase the likelihood of requiring a revision, leading to increased costs and possible complications \[[@CR7]\]. It is therefore important to consider treatment options available that may alleviate symptoms related to knee OA and delay the need for primary TKA in order to reduce the likelihood of requiring a revision TKA.

The use of intra-articular hyaluronic acid (IA-HA) as a treatment method for knee OA presents a non-surgical option for symptom relief which may provide better results than other conservative treatment options \[[@CR8], [@CR9]\]. Evidence also suggests that the use of IA-HA preparations may safely delay the time to arthroplasty \[[@CR10], [@CR11]\]. The IA-HA preparation Euflexxa (1% sodium hyaluronate) has been shown to be a cost-effective method of treating the symptoms associated with knee OA; however, the current and potential economic impact of this form of treatment on the US population has yet to be determined \[[@CR12]\].

The purpose of this study is to determine the current and potential impact that a biologically derived high molecular weight IA-HA (Euflexxa) may have on quality adjusted life years (QALY) if used more widely for patients suffering with knee OA.

Methods {#Sec2}
=======

Ethics Statement {#Sec3}
----------------

This article does not contain any new studies with human or animal subjects performed by any of the authors.

Study Scope and Model Generation {#Sec4}
--------------------------------

We modelled the total number of patients in the USA (2015) with symptomatic knee OA, distributed across Kellgren--Lawrence (K--L) OA severity grades, and the current number of patients with TKA. Using these estimates, we projected the total number of eligible patients who may benefit from the use of Euflexxa versus conventional care in the USA.

The model was developed to provide an estimate for the prevalence of symptomatic knee OA in the USA in 2015. Estimates for the prevalence of symptomatic knee OA in the USA were obtained from the American Academy of Orthopaedic Surgeons (AAOS) \[[@CR3]\], and estimates on the incidence of knee OA, prevalence of TKA, and incidence of TKA were obtained from the published literature \[[@CR13]--[@CR15]\] (Table [1](#Tab1){ref-type="table"}). The portion of the population who have undergone a TKA was omitted from the model, given that they have already received definitive knee OA treatment and would no longer be eligible to benefit from an IA-HA injection. As incidence data was sourced from 1995, the prevalence per 100,000 person/years was taken and adjusted for the age and sex distribution for 2015 \[[@CR13]\]. It was estimated that there were 9.9 million people with symptomatic knee OA in the USA in 2010, and that the annual incidence of symptomatic knee OA in the US is approximately 770,000 (Table [1](#Tab1){ref-type="table"}).Table 1US OA demographic valuesVariablePast estimates (year)2015 estimateUS symptomatic knee OA prevalence9,900,000 (2010)^a^12,338,273US OA incidence768,494 (1995)^b^605,598US TKA prevalence4,000,000 (2013)^c^5,240,455US TKA incidence671,374 (2012)^d^--US death rate in adults \>351.026% (2007)^e^--K--L grade 130.0% (2009)^f^2,130,382K--L grade 227.3% (2009)^f^1,939,724K--L grade 329.2% (2009)^f^2,074,428K--L grade 413.4% (2009)^f^953,283Total eligible patients--4,014,153Current Euflexxa use276,168 (2014)^g^276,168Current other IA-HA use962,185 (2014)^g^962,185Total eligible non-HA users--3,051,968^a^AAOS, 2010^b^Oliveria, 1995 \[[@CR13]\]^c^Weinstein, 2013 \[[@CR14]\]^d^Healthcare Cost and Utilization Project, 2015 \[[@CR15]\]^e^Centers for Disease Control and Prevention, 2015 \[[@CR18]\]^f^Multicenter Osteoarthritis Study, 2010 \[[@CR16]\]^g^IMS, 2014 \[[@CR17]\]

The distribution of patients with knee OA by K--L severity grades was obtained from a large observational study on knee OA involving 3021 people surveyed in the US population \[[@CR16]\]. The majority of studies examining IA-HA involved participants with K--L grades of 2--3, so the percentage of the symptomatic OA population with K--L grades 2 and 3 was calculated to determine the total number of patients eligible to benefit from IA-HA injections. Patients across all K--L levels who had not received a TKA or were currently using IA-HA were considered eligible to receive appropriate conventional care. The current use of Euflexxa and other IA-HA products was obtained through the IMS claims data for 2014 \[[@CR17]\].

The mortality rate corresponding to the demographics of the model population was used, under the previously validated assumption that mortality amongst the OA population is similar to that of the general US population \[[@CR18]--[@CR20]\]. Data on utility scores for the healthy US population was obtained from the literature \[[@CR21]\].

The changes in health state of patients receiving treatment was reported in terms of a utility score, represented in QALYs, a frequently used quality of life measurement in health economic analyses. QALYs are determined by using utility values that represent desired health states which, for a single patient, vary from 0 (indicating death) to 1 (indicating perfect health) \[[@CR22]\]. In order to determine the impact of a treatment, the number of eligible patients for the treatment was multiplied by the increase in utility score resultant from that treatment.

Total QALYs saved within the population of patients with symptomatic knee OA in the USA for 1 year was calculated for the following three scenarios: (1) all eligible patients with knee OA receiving no treatment versus current Euflexxa use; (2) current Euflexxa use versus use in all eligible patients with knee OA; and (3) all eligible patients with knee OA receiving no treatment versus all eligible patients receiving Euflexxa.

OA Prevalence and TKA Prevalence Calculations {#Sec5}
---------------------------------------------

The prevalence of symptomatic knee OA in the USA for the year 2015 was estimated according to the formula$$\documentclass[12pt]{minimal}
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                \begin{document}$$ f^{5} \left( x \right) \, = \, \left( {x + y} \right) \, - \, \left( {x + y} \right) \times z $$\end{document}$$where *x* is the 2010 symptomatic knee OA prevalence, *y* is the symptomatic knee OA incidence, and *z* is the US death rate for adults over 35.

A similar formula was used to estimate the prevalence of TKA in the US population:$$\documentclass[12pt]{minimal}
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                \begin{document}$$ f^{2} \left( a \right) \, = \, \left( {a + b} \right) \, - \, \left( {a + b} \right) \times z $$\end{document}$$where *a* is the 2013 TKA prevalence, *b* is the TKA incidence, and *z* is the US death rate for adults over 35.

Both of these formulas are nested formulas, where the number of times the formula is nested corresponds to the superscript number. The nested formula takes the preliminary prevalence, adds the incidence, and subtracts the death rate to gain the prevalence for the following year. This new prevalence is then the starting point for the next iteration of the formula, which is repeated for the number of times specified.

Treatment {#Sec6}
---------

The treatment option examined in this study is the high molecular weight IA-HA injection Euflexxa. In a randomized controlled trial (the FLEXX trial), Altman et al. examined this preparation over two courses of three injections, with 6 months between each course of treatment \[[@CR23]\]. As a comparator, we used appropriate conservative care (henceforth referred to as "appropriate care"), which was defined as all non-IA-HA treatments (NSAIDS and other analgesics, physiotherapy, weight loss, ambulatory aids), and abstracted the data from a randomized controlled trial by Torrance et al. \[[@CR24]\].

Utility Score Calculations {#Sec7}
--------------------------

Baseline and treatment utility scores for Euflexxa over the course of a year were abstracted from Hatoum et al. \[[@CR12]\], plotted, and the area under the curve between the two treatments was calculated for the total QALYs gained over 1 year. To model those receiving no treatment, baseline scores were extrapolated over a year with the assumption that their condition would neither worsen nor improve. Utility score information for appropriate care was obtained from Torrance et al., which compared baseline utility scores to scores following one year of appropriate care \[[@CR24]\]. Utility scores for the US population across different age groups were abstracted from previously published EQ-5D data \[[@CR22]\]. Since patients who receive IA-HA as a treatment method also receive aspects of appropriate care in addition to the injections, the QALY of appropriate care was subtracted from the QALY of the IA-HA preparation to account for gains potentially attributed to the use of appropriate care.

Economic Impact Calculation {#Sec8}
---------------------------

The current and potential impact of each treatment was calculated by multiplying the utility score of the treatment for one person over the course of a year by the number of people currently using, or eligible to use the treatment, respectively. The current impact of Euflexxa was determined by comparing the current use of Euflexxa to no use. The potential impact of Euflexxa was determined by modelling the utility of all eligible patients using Euflexxa and comparing it to the modelled utility of both current use and no use.

Sensitivity Analysis {#Sec9}
--------------------

Sensitivity analysis was conducted to evaluate the robustness of the results, and to provide confidence intervals to account for potential variation in both the population of eligible patients and the efficacy of the treatment. This was evaluated by performing a two-way sensitivity analysis by increasing and decreasing both the number of eligible patients and the utility score of Euflexxa by ±20%.

Sensitivity analysis was also performed to provide insight into potential uncertainties in certain input domains. The current use of Euflexxa was determined from IMS claims data in 2014; however, as this value may have either increased or decreased in 2015, a two-way sensitivity analysis was performed on the current use of Euflexxa. In addition, there is some uncertainty as to whether the mortality rate of persons with OA is similar to or higher than that in the general population \[[@CR18]--[@CR20], [@CR25]\]. In order to consider this uncertainty, a two-way sensitivity analysis was performed adjusting the mortality rate.

Results {#Sec10}
=======

Knee OA Prevalence in the USA {#Sec11}
-----------------------------

The estimate for the number of people with symptomatic knee OA in the USA in 2015 is therefore approximately 12.3 million. The model estimated the prevalence of patients who have received a TKA in the USA to be approximately 5.2 million, which left 7.1 million people in the USA with symptomatic knee OA who have not received a TKA. The number of patients with K--L 2--3 OA was determined to be 4.0 million, or roughly 32% of the population who have symptomatic knee OA \[[@CR17]\]. To determine the number of patients eligible for Euflexxa injection, the number of patients receiving other forms of IA-HA were subtracted (*n* = 962,185), leaving 3.0 million eligible patients, of which 276,168 are currently using Euflexxa \[[@CR18]\].

Utility Scores {#Sec12}
--------------

A calculation of the area under the curve between baseline and treatment over 1 year for the use of Euflexxa indicated that there was 0.163 QALYs gained per year per person, while the effectiveness of appropriate care was determined to be 0.03 QALYs gained per person per year \[[@CR24]\]. The QALYs gained per person per year for Euflexxa when accounting for the concomitant use of appropriate care was therefore considered to be 0.133 QALYs.

Current Impact of Euflexxa {#Sec13}
--------------------------

Figure [1](#Fig1){ref-type="fig"} shows the 1-year QALY for a healthy individual, an OA patient receiving no treatment, and an OA patient receiving Euflexxa, and for a 62-year-old (mean age of the FLEXX trial treatment group) \[[@CR23]\]. The current estimate for the number of QALYs saved by Euflexxa is 36,730 QALY/year when comparing current use to no use (Table [2](#Tab2){ref-type="table"}).Fig. 1QALY for healthy individual, OA patient receiving no treatment, and OA patient receiving Euflexxa (age 62) Table 2Impact of EuflexxaVariableEuflexxaAppropriate careBaseline utility0.4820.46Post treatment utility0.6450.51QALY gained0.1630.03Current QALY gained per year (current use--no use)36,730--Potential QALY gained per year (maximum use--no use)405,911185,074Potential additional QALY gained per year (maximum use--current use)369,181--

Potential Impact of Euflexxa {#Sec14}
----------------------------

If all 3.0 million eligible symptomatic knee OA patients were to use Euflexxa, then an additional 369,181 QALY/year could be saved in addition to the current impact of Euflexxa. If all eligible patients were treated with Euflexxa, there would be a potential 405,911 QALY/year saved, when compared to not treating any eligible patients with Euflexxa (Table [2](#Tab2){ref-type="table"}).

Comparison to Appropriate Care {#Sec15}
------------------------------

The model determined that 6.2 million patients were eligible for appropriate care. The total number of QALY saved if all eligible patients were to use appropriate care was determined to be 185,074 QALY/year, less than half of the impact of Euflexxa.

Sensitivity Analysis {#Sec16}
--------------------

When evaluating the current use of Euflexxa, the modelled value of 36,730 QALY/year saved ranged from 23,507 to 52,891 QALY saved, when both the number of eligible patients and the utility score of Euflexxa were adjusted by ±20% (Table [3](#Tab3){ref-type="table"}). The range of values for the additional QALY/year saved, if all potential patients used Euflexxa, was 287,999--450,363 QALY/year for a potential total range of 324,729--487,094 QALY saved per year. The sensitivity analysis for the potential maximum QALY/year saved by appropriate care revealed that the impact ranged from 118,447 to 266,506 QALY/year.Table 3Sensitivity analysisNumber of eligible patientsQALY and impactHighLowQALYImpactQALYImpactEuflexxaCurrent useHigh331,4010.159652,8910.106435,261Low220,93435,26123,507AdditionalHigh3,330,960531,621354,414Low2,220,640354,414236,276MaximumHigh3,662,362584,512389,675Low2,441,574389,675259,783Appropriate careMaximumHigh7,402,9640.036266,5060.024177,671Low4,935,309177,671118,447

The sensitivity analysis examining the current use of Euflexxa determined that for the modelled 276,168 patients the lower and upper limits of the sensitivity were 220,934 and 331,401, respectively. These limits corresponded to the originally modelled 36,730 QALY/year adjusting to 44,076 QALY/year for the upper limit and 29,384 QALY/year for the lower limit. When examining mortality rate, it was found that a 20% decrease in the mortality rate increased the number of persons with symptomatic knee OA to 12,454,377 corresponding to 414,645 QALY/year saved, while an increase in the mortality rate led to a decrease in the persons with symptomatic knee OA to 122,223,078 and an impact of 397,247 QALY/year saved.

Discussion {#Sec17}
==========

The purpose of this study was to evaluate the current and potential impact of a biologically derived, high molecular weight IA-HA preparation (Euflexxa) on the US population with symptomatic knee OA. Our model found that Euflexxa currently saves 36,730 QALY/year, and has the potential to save an additional 369,181 QALY/year if it was to be more widely administered.

Several studies have looked at the cost-effectiveness of various treatments \[[@CR2], [@CR12], [@CR24]\], the lifetime medical costs of treatments \[[@CR26], [@CR27]\], and the impact of OA treatments in European countries \[[@CR28]\]. To our knowledge, this is the first study to measure the current and potential impact of a symptomatic knee OA treatment modality with respect to the total number of QALYs saved per year across the entire US population. The lack of literature demonstrating the impact of other treatment methods makes it difficult to compare the impact of Euflexxa to other treatment modalities; however, we were able to compare our intervention to appropriate care, which covers all other forms of non-operative treatment.

Previous literature has shown that treatment of knee osteoarthritis with IA-HA, and specifically with biologically derived hyaluronic acid (Bio-HA), is a cost-effective treatment option over appropriate care \[[@CR12], [@CR25]\]. The results of this study also demonstrate a difference in the potential impact of these two treatment methods. While appropriate care had a larger eligible patient base compared to Euflexxa (50% versus 34% of all symptomatic knee OA patients, respectively), Euflexxa still demonstrated an overall larger impact on the symptomatic knee OA population by more than double (405,911 QALY/year to 185,074 QALY/year, respectively).

Several assumptions were made within this study which may be limitations of the accuracy of the model. The first assumption is that only patients with K--L 2 or 3 are eligible for the use of Euflexxa. It is possible for patients with K--L 1 and 4 to be prescribed IA-HA, and this assumption may underestimate the total number of patients who may benefit from the use of the treatment. Second, when comparing Euflexxa to appropriate care, two different studies were used, involving patients from different regions and at different times, meaning that the patient populations were not the same and which may result in some unwanted variation. In addition, the health utility index for patients receiving either Euflexxa or appropriate care was derived from different preference measures than the healthy population. This derivation from different initial measures may lead to some potential differences between the QALY scores between the patients with symptomatic knee OA and the healthy population. The utility score data from Hatoum et al. \[[@CR12]\] included data from both the FLEXX trial and extension trial, although the extension was an open label investigation. This creates a potential limitation, as the open label extension trial data may be subject to bias. Finally, there is a lack of information in the current literature regarding suboptimal adherence to an IA-HA injection regimen. For this reason, we used the available evidence for Euflexxa use, which demonstrated no issues with adherence; however, this may not be the case in clinical scenarios.

The present study is strengthened by the sensitivity analysis, which examines potential variation in both the population of eligible patients and the efficacy of the treatment method. The two-way analysis provides a range of the current and potential impacts on the US population based on up to a 20% increase or decrease in both the eligible population and the utility score of the treatment method.

Conclusion {#Sec18}
==========

This study has shown that, if more widely used, a biological fermentation-derived, high molecular weight IA-HA preparation, such as Euflexxa, has the potential to save substantial QALY per year within the USA; this is more than twice as much as appropriate care. Further studies examining the impact of additional treatment methods on the US population will allow further comparison between OA treatment strategies.
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